Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study)

Inclusion Criteria:

- Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa
(HS) for at least 1 year (365 days) prior to the Baseline visit

- Participant must have at least 3 distinct anatomical regions involved with
inflammatory ( also termed 'active') HS lesions; plus

- either one axilla or one inguinal region (limited to the inguino-crural fold and
adjacent areas) that requires excisional surgery, and

- with at least one of the other affected HS regions (e.g., contralateral inguinal
region, buttocks, inframammary region) rated as Hurley Stage II or III

- Participant must have a total abscess and inflammatory nodule (AN) count of greater
than or equal to 3 at the Baseline visit within the HS non-surgical sites

- The HS surgical site must contain at least one active HS lesion

- The HS surgical site must require excisional surgery and is large enough to require
healing by secondary intention as assessed by the designated surgeon

Exclusion Criteria:

- Has a draining fistula count of greater than 20 at the Baseline visit

- Requires surgery at any anatomical site other than an unilateral axilla or inguinal
region site

- Requires surgical management prior to Week 13

- Requires, based on the designated surgeon's assessment, excisional surgery with
primary closure as the method of closure being most beneficial for the participant